The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil
复制标题
DOI：
10.1159/000028401
复制
发表时间：
2000-01-01
期刊：
影响因子：
3.1
通讯作者：
Johnson, MR
中科院分区：
文献类型：
--
作者：
Diasio, RB;Johnson, MR
越来越多的证据支持遗传学在决定影响中的重要作用这包括药物遗传学和药物基因组学，在药物遗传学中，编码重要药物代谢酶的基因的改变导致毒性增加和偶尔改变的功效，其中对癌症化疗药物的作用至关重要的基因表达的知识可用于个体化治疗。本文以广泛使用的癌症化疗药物5-氟尿嘧啶（5-FU）为例，阐述以下概念：（1）被称为二氢嘧啶脱氢酶（DPD）缺乏症的药物遗传学综合征对5-FU药理学的影响;（2）药物基因组学在5-FU个体化治疗中的作用;（3）药物基因组学在新药设计中的潜在价值。版权所有（C）2000 S. KargerAG，巴塞尔。
There is increasing evidence supporting the important role of genetics in determining the effect (response and toxicity) to cancer chemotherapy, This has included both pharmacogenetics, where the alteration of a gene coding for an important drug metabolizing enzyme results in increased toxicity land occasionally altered efficacy), and pharmacogenomics, where knowledge of the expression of genes critical to the action of the cancer chemotherapy drug can be used to individualize therapy. This manuscript focuses on the widely used cancer chemotherapy drug 5-fluorouracil (5-FU) to illustrate the following concepts: (1) The effect of the pharmacogenetic syndrome known as dihydropyrimidine dehydrogenase (DPD) deficiency on 5-FU pharmacology; (2) the role of pharmacogenomics in individualizing 5-FU therapy, and (3) the potential value of pharmacogenomics in designing new drugs. Copyright (C) 2000 S. KargerAG, Basel.